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Abstract  
BACKGROUND: As previously various studies have suggested application of brain-derived 
neurotrophic factor (BDNF) may be considered as a promising future therapy for hearing deficits, in 
particular for the improvement of cochlear neurone loss during cochlear implantation.
 
AIM: The present study's aim was to establish the upper threshold of the concentration of BDNF in 
Naval Medical Research Institute (NMRI) mice spiral ganglion outgrowth. 
 
METHODS: Spiral ganglion explants were prepared from post-natal day 4 (p4) (NMRI) mice of both 
sexes under the approval and guidelines of the regional council of Hearing Research Institute 
Tubingen.  
RESULTS: Spiral ganglion explants were cultured at postnatal days 4 in the presence of different 
concentrations of BDNF as described under methods. We chose an age of postnatal day (P4) and 
concentrations of BDNF 0; 6; 12.5; 25 and 50 ƞg/ml. Averaged neurite outgrowth is measured in 4 
different cultures that were treated with different concentrations. Results show that with increasing 
concentrations of BDNF, the neurite density increases. 
CONCLUSION: The present finding show evidence that BDNF has a clear incremental effect on 
the number of neurites of spiral ganglia in the prehearing organ, but less on the neurite length. The 
upper threshold of exogenous BNDF concentration on spiral ganglion explant is 25 ƞg/ml. This 
means that concentration beyond this level has no further incremental impact. Therefore our 
suggestion for hydrogel concentration in NMRA mice in future research should be 25 ƞg/ml.
 
 
 
 
 
 
Introduction 
 
Over the past 20 years, cochlear implants 
(CIs) have been developed to improve hearing in 
patients with hearing impairment [1]. The CI is among 
the most important medical and biotechnological 
achievements because it allows individuals who had 
never heard or had lost their hearing to perceive 
sound [1, 2]. The levels to which neurotrophic factors 
can rescue the auditory nerve from differentiation-
induced degeneration and promote regrowth are of 
both basic scientific and clinical interest [2]. Such 
regrowth may enhance the therapeutic efficacy of 
cochlear prostheses [3, 4]. In 2014, Pinyon and 
colleagues tested gene therapy on deaf guinea pigs 
[1]. Briefly, guinea pigs were made deaf with a drug 
that destroyed cochlear hair cells, and then cDNA 
encoding brain-derived neurotrophic factor (BDNF) 
was delivered to the cochlea by electroporation. The 
successful entry was detected using green fluorescent 
protein as a reporter. The electroporated cells began 
to release BDNF, which stimulated the outgrowth of 
neurones in the direction of the electrodes. The 
results were much better with added BDNF. However, 
the new nerves began to die because the cells no 
longer produced BDNF [5, 6]. Modification of the 
electroporated cDNA may facilitate the longer-term 
production of BDNF in the cells. 
 
The present study was performed to calculate 
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the upper threshold of exogenous BDNF 
concentration in spiral ganglion outgrowth. 
 
 
Materials and Methods 
 
Our institutional ethics committee provided 
approval for this research on 10 June 2009. This 
study was performed by German laws regulating the 
use of animals in laboratory and experiments for 
research purposes (TSchG, 4§ (3)). All international 
and EU ethical norms were rigorously respected. All 
data were collected and processed using Microsoft 
Excel (Microsoft, Redmond, WA, USA) and SPSS 
17.0 (SPSS, Chicago, IL, USA). The requirement for 
informed consent was waived due to the nature of the 
study. 
 
Spiral ganglion explant culture 
Spiral ganglion explant cultures were 
prepared from postnatal day 4 (p4) Naval Medical 
Research Institute (NMRI) mice of both sexes by the 
guidelines of the regional council. The animals were 
rapidly decapitated in accordance with German laws 
governing the care and use of animals (TSchG, §4 
(3)). All subsequent procedures were performed under 
sterile conditions with confocal microscopy (Zeiss, 
Oberkochen, Germany). The skin was removed, and 
the skull was opened mid-sagittally. For this 
experiment, 20 mice were sacrificed, one mouse per 
ear. After removal of the brain, the temporal bone was 
harvested and transferred to a sterile petri dish filled 
with ice-cold HEPES-buffered Hanks' balanced salt 
solution (HHBSS). The bony capsule of the cochlea 
was removed to expose the membranous parts of the 
cochlea. The stria vascular, the organ of Corti, and the 
bone around the modiolus were removed, separating 
the entire spiral ganglion. The apical part of the spiral 
ganglion was transferred into a sterile culture dish 
coated with laminin, poly-D-lysine, collagen, and 
fibronectin (BD Biosciences, Franklin Lakes, NJ, 
USA). Spiral ganglion cultures were cultivated in 
serum-free medium. Neurobasal media was enriched 
by adding 2% B27 supplement, 0.2% penicillin, two 
mM HEPES, and 2.5% glutamine. BDNF (R&D 
Systems, Wiesbaden, Germany) was added to the 
medium. Cultivation was performed in an incubator 
(Heraeus, Hanau, Germany) at 37°C with 95% 
humidity and 5% CO2 for 96 hours.  
 
Spiral ganglion explant 
immunocytochemistry 
Spiral ganglion explants were fixed in 4% 
paraformaldehyde in phosphate-buffered saline 
(PBS), (Invitrogen, Karlsruhe, Germany) for 20 
minutes, washed, and permeabilised with PBS 
containing 0.2% Triton-X for 5 minutes. Non-specific 
binding was blocked by incubation with 1% bovine 
albumin serum in PBS for 1 hour. Explants were 
incubated with primary antibodies, anti-neurofilament 
200 kDa (NF200), and anti-glial fibrillary acidic protein 
(anti-GFAP) (1:800 dilution) at 4°C overnight. After 
three washes in 0.2% Triton-X in PBS, secondary 
fluorescence-labelled antibodies (cyan (Cy3) and 
Alexa 488) were added at a dilution of 1:400 (Table 
1). The spiral ganglion explants were incubated for 1 
hour at room temperature. Cell bodies were marked 
with 4',6-diamidino-2-phenylindole (DAPI) fluorescent 
DNA stain. Explants were rinsed with PBS, mounted 
on the microscope slide with fluorescent dye [with 
Alexa Fluor (Thermo Fisher Scientific, Waltham, MA, 
USA) and observed under normal epifluorescence 
using a Zeiss microscope. We counted only the 
number of neurites and not their length, as this 
experiment focused only on the trophic effect. 
Table 1: Dual staining for identification of receptors on 
neurones in explants of immature spiral ganglia treated with 6, 
12.5, 25, or 50 ng/ml BDNF at P4
 
Primary and 
secondary 
antibodies   
0 
ng/ml 
BDNF
1
 
6 
ng/ml 
BDNF 
12.5 
ng/ml 
BDNF 
 25 
ng/ml 
BDNF 
50 
ng/ml 
BDNF 
Category-Number   
Neurofilament 
200 mouse  
1:400 1:400 1:500 1:800 1:800 Sigma #0142  
GFAP
2
  rabbit 1:400 1:400 1:600 1:800 1:800 
DakoCytomation 
#Z0334 
Cy 3
3
 goat anti-
rabbi 
1:400 1:400 1:400 1:400 1:1000 
ImmunoResearch 
Jackson 
800/367/5296 
1, Brain-derived Neurotrophic Factor; 2, Glial Fibrillary Acid Protein; 3, Cyan 3 (colour).
 
 
As described in the Methods section, spiral 
ganglion explants were cultivated in the presence of 
different concentrations of BDNF at postnatal day 4 
(P4). Specifically, at P4, samples were treated with 
different concentrations of exogenous BDNF: group 1 
(control), 0 ng/ml; group 2; 6 ng/ml; group 3,;12.5 
ng/ml; group 4; 25 ng/ml; and group 5,;50 ng/ml. 
Twenty spiral ganglia were used in this experiment 
(four ears per group).  
 
Statistical analysis 
All data were analysed and are expressed as 
means ± standard deviation. Statistical analyses were 
conducted using Microsoft Office Excel 2013. The 
median neurite number, standard deviation, and p-
value are shown in Table 2. The Kruskal–Wallis H test 
was used to determine the statistical significance of 
differences involving five independent variables. The 
significance of differences between groups was 
examined with the Mann–Whitney test using SPSS. In 
this study, the mean is indicated by the x-bar symbol 
( x ), the standard deviation is indicated by SD, the 
median is indicated by Me, and the 95% confidence 
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interval is expressed as 95%
 
CI. In all analyses, P < 
0.05 was taken to indicate statistical significance. 
 
 
Results 
 
The Kruskal–Wallis H test indicated 
statistically significant differences in individual neurite 
numbers among the different BDNF concentrations (H 
= 15.542, DF = 4, p = 0.002371): BDNF = 0 ng/ml, 
mean rank, 2.5.  
The K statistic was 16.542733, and there 
were four degrees of freedom.  
The significance of differences between 
groups was tested with the Mann–Whitney test. There 
were no significance differences between groups 4/5 
(p = 0.88). The correction was performed with 
Bonferroni test. There were significance differences 
among groups except groups 4/5.  
Table 2: Neurite number in spiral ganglion explants treated 
with 6, 12.5, 25, or 50 ng/ml BDNF at P4 
BDNF concentration 
(ng) 
Individual neurite 
number 
Statistics 
0 
4 x  = 11.5 
16 SD = 5.45 
11 95% CI = 5.36 – 17.63 
15 n = 4, Mean rank = 2.5 
6 
20 x  = 29.0 
35 SD = 6.48 
29 95% CI = 22.87 – 35.13 
32 n = 4, Mean rank = 8.0 
12.5 
21 x  = 31.5 
34 SD = 8.35 
30 95% CI = 25.37 – 37.63 
41 n = 4, Mean rank = 9.0 
25 
55 x  = 50.0 
44 SD = 4.65 
51 95% CI = 43.37 – 55.63 
48 n = 4, Mean rank = 16.37 
50 
52 x  = 50.0 
50 SD = 1.63 
48 95% CI = 43.87 – 56.13 
50 n = 4, Mean rank = 16.62 
Kruskal–Wallis test H 
H = 16.542733 
(DF = 4, n = 20) p = 0.002371 
 
 
A)
 
B)
 
C) 
 
D) 
 
E) 
 
 
F) 
 
 
Figure 1: Spiral ganglion explants of NMRI mouse at P4. Staining performed with anti-NF200 and anti-GFAP antibodies. Scale bar 
represents 500 µm. 352 x 352 mm (72 x 72 DPI). A) BDNF = 0 ng/ml, mean rank, 2.5; B) BDNF = 6 ng/ml, mean rank, 8.0; C) BDNF = 12.5 
ng/ml, mean rank, 9.0; D) BDNF = 25 ng/ml, mean rank, 16.37; E) BDNF = 50 ng/ml, mean rank, 16.62; F) Neurite number in spiral 
ganglion explants with 0, 6, 12.5, 25 ng, or 50 ng/ml BDNF at P4.  
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Discussion 
 
Sensorineural hearing loss is caused by loss 
of neurotrophic factors, leading to cochlear hair cell 
damage, which is followed by degeneration of spiral 
ganglion cells [7–10]. 
Schwieger et al. reported that the functionality 
of CIs is dependent on the number and excitability of 
surviving spiral ganglion neurones (SGNs) [11]. 
Spatial separation between the SGNs located in the 
bony axis of the inner ear and the CI, which is inserted 
into the scala tympani, results in suboptimal 
performance in CI patients and may be decreased by 
attracting the SGN neurites toward the electrode 
contacts. Neurotrophic factors, including BDNF, can 
support neuronal survival and neurite outgrowth [12–
14]. Postnatal Sprague–Dawley rats (P2–4) of both 
sexes were dissected to harvest tissue for cell culture 
experiments. The number of seeded neurones was 
determined after 4 hours of incubation. 
 
Neuron-specific staining of the control 
indicated 805.6 ± 90 neurones/well. The survival rates 
under various conditions were calculated by 
determining the number of surviving neurones about 
the mean seeding density of the respective plate. 
After two days of incubation, the untreated control 
showed a survival rate of 3.57% ± 0.52%. Compared 
with the negative control, the neuronal survival rates 
in wells treated with 50 ng/ml BDNF (18.64% ± 0.79%) 
or 100 ng/ml ciliary neurotrophic factor (CNTF) 
(12.51% ± 2.27%) were significantly increased (BDNF: 
p < 0.001; CNTF: p < 0.01). BDNF showed a 
significantly higher neuroprotective effect than CNTF 
(p < 0.05). The highest neuronal survival rate was 
observed in SGNs treated with a combination of 50 
ng/ml BDNF and 100 ng/ml CNTF (40.69% ± 3.52%; p 
< 0.001) compared with all other conditions. We 
concluded that the combination of BDNF and CNTF 
has great potential to increase both neuronal survival 
and the number of bipolar neurones in vitro and to 
regenerate retracted nerve fibres. 
In agreement with our study, BDNF has been 
shown to increase the number of SGNs with 
increasing levels of exogenous BDNF [15–17]. This 
effect was demonstrated in this study in groups 
treated with different exogenous BDNF 
concentrations, ranging from 0 to 25 ng/ml. The 
results reflected significant differences in the numbers 
of individual neurites according to the different BDNF 
concentrations (H = 15.542, DF = 4, p = 0.002371): 
BDNF = 0 ng/ml, mean rank, 2.5; BDNF = 6.25 ng/ml, 
mean rank, 8.0; BDNF = 12.25 ng/ml, mean rank, 9.0; 
BDNF = 25, mean rank, 16.37; and BDNF = 50 ng/ml, 
mean rank, 16.62. To avoid the influence of other 
substances, such as CNTF, we used purely 
exogenous BDNF added to the cell culture medium. 
 
Studies with other animals using similar 
methods yielded similar results [17]. Lake et al. 
reported that treating deafened cats with 
neurotrophins can improve SGN survival and 
functionality [17–24]. Neonatal deafened cats 
provided the first evidence of the neurotrophic effects 
of BDNF in the developing auditory system [24–25]. 
We used NMRI mice at P4 in the present study and 
concluded that BDNF has an increasing effect on the 
number of SGNs in this animal model.  
Stöver et al. reported that intracochlear 
administration of BDNF (50 ng/ml) for 14 days starting 
on the seventh day after ototoxic treatment resulted in 
significantly improved survival of SGNs. They also 
demonstrated that BDNF, NT-3, NT-4/5, and NGF, 
each administered at a concentration of 62.5 µg/ml, 
can prevent the further degeneration of these cells 
after 14 days of deafness. Even where therapy with 
BDNF + FGF, NT-3 or CNTF was delayed until 1–6 
weeks after deafening, this therapy still significantly 
protected the cells from degeneration [26]. 
Our results agreed with this previous study in 
that 50 ng/ml of exogenous BDNF resulted in 
significantly improved SGN survival. In the present 
study, however, there were no significant differences 
in neurite number or outgrowth between spiral 
ganglion explant groups 4 and 5 treated with 25 ng/ml 
and 50 ng/ml BDNF, respectively (p = 0.88). Thus, it 
would be possible to reduce the costs associated with 
the use of hydrogel containing BDNF by using a lower 
concentration while achieving the same clinical effect. 
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